Abstract
Oxidized low-density lipoprotein (OxLDL) is a well-known risk marker for cardiovascular diseases. OxLDL has shown a variety of proatherogenic properties in experiments performed in vitro. In addition, immunological studies using monoclonal antibodies have revealed the occurrence of OxLDL in vivo in atherosclerotic lesions and patients’ plasma specimens. Resent clinical studies have indicated the prospective significance of plasma OxLDL measurements; however, the behavior and metabolism of OxLDL in vivo is poorly understood. The mechanism by which LDL is oxidized is not clear, and the modified structures of OxLDL are not yet fully understood, partly because OxLDL is a mixture of heterogeneously modified particles. Here, I discuss the recent studies on oxidative modifications in OxLDL and its clinical and pathological features.
Similar content being viewed by others
References
Stocker R (1994) Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 5:422–433
Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala-Korpela M (2000) Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta 1488:189–210
Witztum JL, Steinberg D (1991) Role of oxidized low density lipoprotein in atherosclerosis. J Clin Invest 88:1785–1792
Itabe H (1998) Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res 37:181–207
Uchida K, Stadtman ER (1992) Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci U S A 89:4544–4548
Podrez EA, Abu-Soud HM, Hazen SL (2000) Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28:1717–1725
Hazen SL, Heinecke JW (1997) 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99:2075–2081
Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh-ishi S, Steinbrecher UP et al (1997) Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atheroscleorotic intima. J Biol Chem 272:1433–1436
Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13:1176–11874
Stadtman ER (1992) Protein oxidation and aging. Science 257:1220–1224
Itabe H, Jimi S, Kamimura S, Suzuki K, Uesugi N, Imanaka T et al (1998) Appearance of cross linked proteins in human atheroma and rat pre-fibrotic liver detected by a new monoclonal antibody. Biochim Biophys Acta 1406:28–39
Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T et al (1994) A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholine and polypeptides. J Biol Chem 269:15274–15279
Itabe H, Yamamoto H, Imanaka T, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, Takano T (1996) Oxidized phosphatidylcholines that modify proteins. Analysis by anti-oxidized low density lipoprotein monoclonal antibody. J Biol Chem 271:33208–33217
Imanaga Y, Sakata N, Tekebayashi S, Matsunaga A, Sasaki J, Arakawa K et al (2000) In vivo and in vitro evidence for glycoxidation of low density lipoprotein in atherosclerotic plaques. Atherosclerosis 150:343–355
Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H et al (2006) Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 43:506–514
Suzuki M, Kamei M, Itabe H, Yoneda K, Bando H, Kume N et al (2007) Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis 13:772–778
Akagi M, Kanata S, Mori S, Itabe H, Sawamura T, Hamanish C (2007) Possible involvement of the oxidized low-density lipoprotein/lectin-like oxidized low-density lipoprotein receptor-1 system in pathogenesis and progression of human osteoarthritis. Osteoarthr Cartil 15:271–290
Naba I, Yoshikawa H, Sakoda S, Itabe H, Suzuki H, Kodama T, Yanagihara T (2000) Onion-bulb formation after a single compression injury in the macrophage scavenger receptor knockout mice. Exp Neurol 166:83–89
Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL (1996) Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98:800–814
Binder CJ, Hörkkö S, Dewan A, Chang M-K, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ (2003) Pneumococcal vaccination decrease atheroscleostic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9:736–743
Rosenfeld ME, Khoo JC, Miller E, Parthasarathy S, Parinski W, Witztum JL (1991) Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid–protein adducts. J Clin Invest 87:90–99
Toyokuni S, Miyake N, Hiai H, Hagaiwara M, Kawakishi S, Osawa T, Uchida K (1995) The monoclonal antibody specific for the 4-hydroxy-2-nonenal histidine adduct. FEBS Lett 359:189–191
Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y et al (1998) Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 95:4882–4887
Kawai Y, Saito A, Shibata N, Kobayashi M, Yamada S, Osawa T et al (2003) Covalent binding of oxidized cholesteryl esters to protein: implications for oxidative modification of low density lipoprotein and atherosclerosis. J Biol Chem 278:21040–21049
Haberland ME, Fong D, Cheng L (1988) Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 241:215–218
Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M (1994) Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215:121–125
Ichihashi K, Osawa T, Toyokuni S, Uchida K (2001) Endogenous formation of protein adducts with carcinogenic aldehydes: implications for oxidative stress. J Biol Chem 276:23903–23913
Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D (1995) Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95:2611–2619
Holvoet P, Macy E, Landeloos M, Jones D, Jenny NS, Van de Werf F, Tracy RP (2006) Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 52:760–764
Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, Yamamoto I, Yasuda T, Khamashta MA, Hughes GRV, Koike T, Voelker DR, Matsuura E (2003) Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44:716–726
Kobayashi K, Tada K, Itabe H, Ueno T, Liu PH, Tsutsumi A, Kuwana M, Yasuda T, Shoenfeld Y, de Groot PG, Matsuura E (2007) Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 16:929–938
Matsuura E, Kobayashi K, Tabuchi M, Lopez LR (2006) Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 45:466–486
Chang MK, Binder CJ, Torzewski M, Witztum JL (2002) C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 99:13043–13048
Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM (1990) Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85:1260–1266
Ishikawa K, Navab M, Leitinger N, Fogelman AM, Lusis AL (1997) Induction of heme oxygenase-1 inhibits monocyte transmigration induced mildly oxidized LDL. J Clin Invest 100:1209–1216
Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276:1923–1929
Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL et al (2003) Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol 23:1197–1203
Watson AD, Leitinger N, Navab M, Faull KF, Hörkkö S, Witztum JL et al (1997) Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interaction and evidence for their presence in vivo. J Biol Chem 272:13597–13607
Watson AD, Subbanagounder G, Welsbie DS, Faull KF, Navab M, Jung ME et al (1999) Structural identification of novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J Biol Chem. 274:24787–24798
Podrez EA, Poliakov E, Zhongzhou S, Zhang R, Deng Y, Sun M et al (2002) Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 277:38503–38516
Friedman P, Hörkkö S, Steinberg D, Witztum JL, Dennis EA (2002) Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem 277:7010–7020
Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM (1989) An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem 264:5331–5334
Nabav M, Berliner JA, Sabbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481–488
Zalewski A, Macphee C (2005) Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25:923–931
Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H et al (1996) Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37:45–53
Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otuska M et al (2001) Oxidized low density lipoprotein relates to plaque destabilization in human coronary atherosclerotic lesions. Circulation 103:1955–1960
Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S et al (2000) Hemodialysis impairs endothelial function via oxidative stress. Effects of vitamin E-coated dialyzer. Circulation 101:1002–1006
Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S (2002) Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 22:1649–1654
Uno M, Kitasato K, Nishi K, Itabe H, Nagahiro S (2003) Elevation of plasma oxidized LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry 74:312–316
Itabe H, Hosoya R, Karasawa K, Jimi S, Saku K, Takebayashi S et al (1999) Metabolism of oxidized phosphatidylcholines formed in oxidized low density lipoprotein by lecithin-cholesterol acyltransferase. J Biochem 126:153–161
Penny WF, Ben-Yehuda O, Kuroe K, Long J, Bond A, Bhargava V, Peterson JF, McDaniel M, Julicano J, Witztum JL, Ross J Jr, Peterson KL (2001) Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 37:766–774
Fang JC, Kinlay S, Bhargava V, Hikita H, Witztum JL, Selwyn AP, Ganz P (2006) Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol 26:2044–2048
Tsimikas S, Witzutum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG (2004) High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110:1406–1412
Tsimikas S, Lau HK, Han K-R, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH (2004) Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a). Short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109:3164–3170
Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL (2003) Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. J Am Coll Cardiol 41:360–370
Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, Kanno T, Saito Y (2002) Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 22:662–666
Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lasaffre E, Vanrenterghem Y, Collen D (1996) Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76:663–669
Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F (2001) Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844–1848
Girona J, Manzanares JM, Marinón F, Cabré A, Heras M, Guardiola M, Ribalta J, Masana L (2008) Oxidized to non-oxidized lipoprotein rations are associated with aeteriosclerosis and the metabolic syndrome in diabetic patients. Nutr Metab Cardiovasc Dis 18:380–387
Naruko T, Ueda M, Ehara S, Itoh A, Haze K, Shirai N, Ikura Y, Ohsawa M, Itabe H, Kobayashi Y, Yamagishi H, Yoshiyama M, Yoshikawa J, Becker AE (2006) Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol 26:877–883
Itabe H (2003) Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull 26:1–9
Itabe H, Ueda M (2007) Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 14:1–11
Fyfe AI, Qiao J-H, Lusis AJ (1994) Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest 94:2516–2520
Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H (2000) Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atheroscler 148:171–178
Caligiuri G, Nicoletti A, Poirer B, Hansson GK (2002) Protestive immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109:745–753
Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uni K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y (2008) Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118:75–83
Obama T, Kato R, Masuda Y, Takahashi K, Aiuchi T, Itabe H (2007) Analysis of modified apolipoprotein B-100 structures formed in oxidized low-density lipoprotein using LC-MS/MS. Proteomics 7:2132–2141
Podrez EA, Schmitt D, Hoff HF, Hazen SL (1999) Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103:1547–1560
van Leeuwen M, Gijbels MJJ, Duijvestijn A, Smook M, van de Gaar MJ, Heeringa P, de Winther MPJ, Tervaert LWC (2008) Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesion in LDLR−/− mice. Arterioscler Thromb Vasc Biol 28:84–89
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Itabe, H. Oxidative Modification of LDL: Its Pathological Role in Atherosclerosis. Clinic Rev Allerg Immunol 37, 4–11 (2009). https://doi.org/10.1007/s12016-008-8095-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-008-8095-9